All In Biotech

Investigational drug · Phase 2

BNT116

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Non-Small Cell Lung Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "BNT116"

First trial start

2023

Apr 21, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BNT116", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Non-Small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "BNT116" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Advanced Non-Small Cell Lung Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • FurmonertinibPhase 38 trials

    Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis

  • JSKN016Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

  • QuemliclustatPhase 33 trials

    Arcus Biosciences, Inc. · Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Gastrointestinal Tract Malignancies

  • KN046Recombinant Humanized PD-L1, CTLA-4 Bispecific Single Domain Antibody Fc Fusion ProteinPhase 22 trials

    InxMed (Shanghai) Co., Ltd. · Pancreatic Cancer, Advanced Non-small Cell Lung Cancer

  • QuavonlimabMK-1308Phase 22 trials

    Merck & Co. · Melanoma, Advanced Non-Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.